welcome
CNBC

CNBC

Health

Health

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

CNBC
Summary
Nutrition label

80% Informative

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027 , expanding its ongoing cost savings effort to chart a path toward long-term growth.

The company also issued a full-year 2025 guidance that fell short of Wall Street's expectations, as some of the company's older drugs face competition from cheaper generics.

But Bristol Myers still reported fourth-quarter revenue and adjusted earnings that blew past expectations, boosted by Eliquis and its "growth portfolio" of drugs.

VR Score

91

Informative language

95

Neutral language

90

Article tone

formal

Language

English

Language complexity

39

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links